Robert Nelsen
CIK 1219042 · last filed 2026-10-19
Robert Nelsen is a corporate insider who has filed 133 SEC Form 4 insider transactions across 19 companies since 2012. The most recent filing, for CTY, was dated Oct 19, 2026. Across all open-market trades the lifetime net is +$75.6M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $482.7M across reported positions. 84 SEC filings were submitted jointly with Keith Crandell.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PRME price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1025
CHICAGO, IL 60631
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CTY | Director | 13,522,507 | — | — | $3.06M | 1 | 2026-10-19 |
| PRME | Director | 6,128,297 | $4.30 | $26.35M | $43.60M | 8 | 2026-06-08 |
| SANA | Director | 12,447,375 | $2.46 | $30.68M | $10.00M | 15 | 2026-06-05 |
| LYEL | Director | 910,318 | $15.42 | $14.04M | $0 | 5 | 2024-06-17 |
| VIR | Director | 7,874,803 | $13.64 | $107.45M | $20.00M | 22 | 2024-06-03 |
| BOLD | 10%+ Owner | 617,092 | $2.46 | $1.52M | $3.20M | 1 | 2024-04-04 |
| NMRA | 10%+ Owner | 3,783,387 | $0.49 | $1.84M | $700.5K | 1 | 2023-09-27 |
| DNLI | Director | 9,681,181 | $20.33 | $196.82M | $0 | 8 | 2021-06-04 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | Director | 1,461,704 | $329.83 | $482.11M | $3.20M | 6 | 2021-04-15 |
| BEAM | Director | 3,535,572 | $27.02 | $95.53M | $0 | 3 | 2021-04-02 |
| Unity Biotechnology, Inc. (UBX) Delisted | Director | 168,242 | $0.20 | $33.7K | $0 | 4 | 2020-06-22 |
| Sienna Biopharmaceuticals, Inc. (SNNA) Delisted | Director | 2,538,641 | — | — | $0 | 3 | 2018-06-05 |
| Juno Therapeutics, Inc. (JUNO) Delisted | Director | 3,234 | — | — | $0 | 13 | 2018-03-07 |
| Syros Pharmaceuticals, Inc. (SYRS) Delisted | Director | 463,714 | $0.00 | $185 | $5.00M | 4 | 2017-09-22 |
| AGIO | Director | 118,404 | $31.38 | $3.72M | -$20.75M | 10 | 2017-03-07 |
| Sage Therapeutics, Inc. (SAGE) Delisted | Director | 1,232,649 | $8.68 | $10.70M | $0 | 6 | 2015-11-12 |
| KYTHERA BIOPHARMACEUTICALS INC (KYTH) Delisted | Director | 957,604 | — | — | $0 | 8 | 2015-03-26 |
| Bellerophon Therapeutics, Inc. (BLPH) Delisted | Director | 50,200 | $0.01 | $602 | $2.55M | 1 | 2015-02-23 |
| FATE | Director | 2,473,188 | $1.94 | $4.80M | $5.00M | 1 | 2013-10-07 |
Recent Filings
133 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-10-19 | CTY | Mixed | +10,974,215 | $3.06M | EDGAR |
| 2026-06-08 | PRME | Grant (A) | — | $0 | EDGAR |
| 2026-06-05 | SANA | Grant (A) | — | $0 | EDGAR |
| 2025-08-05 | PRME | Mixed | — | $0 | EDGAR |
| 2025-08-01 | PRME | Buy (P) | +3,030,300 | $10.00M | EDGAR |
| 2025-06-09 | SANA | Grant (A) | — | $0 | EDGAR |
| 2025-06-05 | PRME | Grant (A) | — | $0 | EDGAR |
| 2024-07-15 | SANA | Grant (A) | — | $0 | EDGAR |
| 2024-06-17 | LYEL | Grant (A) | — | $0 | EDGAR |
| 2024-06-14 | PRME | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.